GNH USA

Europe — EMA

Imicilast

GNH USA supplies Imicilast (Imipenem/Cilastatin), a carbapenem antibiotic for complicated intra-abdominal infections, urinary tract infections

Cilastatin, Imipenem Anhydrate

Request sourcing

1
Pack/s

What is Cilastatin, Imipenem Anhydrate?

Imipenem, the active ingredient in Imicilast, is a carbapenem antibiotic presented as an injection for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, urinary tract infections, skin and soft‑tissue infections, nosocomial pneumonia, and meningitis in hospitalized patients.

GNH USA supplies Imicilast as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

What is Cilastatin, Imipenem Anhydrate used for?

Imicilast is a carbapenem antibiotic indicated for serious bacterial infections affecting various organ systems. - Complicated intra‑abdominal infections: provides broad‑spectrum bacterial eradication to resolve infection. - Complicated urinary tract infections: eliminates resistant uropathogens to restore urinary health. - Skin and soft‑tissue infections: treats deep‑seated infections caused by Gram‑negative and Gram‑positive organisms. - Nosocomial pneumonia: combats hospital‑acquired lung infections, including ventilator‑associated pneumonia. - Meningitis: penetrates the cerebrospinal fluid to treat bacterial meningitis caused by susceptible strains.

What are the side effects of Cilastatin, Imipenem Anhydrate?

Adverse reactions may occur with any antimicrobial therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Injection site pain: localized discomfort during administration. - Elevated liver enzymes: transient increase in transaminases.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Severe allergic reactions: anaphylaxis, rash, or angioedema. - Clostridioides difficile colitis: antibiotic‑associated colitis presenting with profuse diarrhea. - Renal dysfunction: acute kidney injury in predisposed individuals.

What precautions apply to Cilastatin, Imipenem Anhydrate?

Imicilast requires careful patient assessment and monitoring. - Renal function: adjust dosing in patients with impaired renal clearance. - Neurological status: monitor for seizures, particularly in those with a history of CNS disease. - Allergies: avoid in patients with known hypersensitivity to carbapenems or β‑lactams. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Drug interactions: review concomitant medications for potential interactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Cilastatin, Imipenem Anhydrate interact with?

Imicilast may interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Valproic acid: increased risk of seizures when combined with carbapenems. - Probenecid: may reduce renal clearance of imipenem, leading to higher plasma levels.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., furosemide): may potentiate nephrotoxic effects; monitor renal function. - Anticoagulants (e.g., warfarin): possible alteration of INR; check coagulation parameters. - Other nephrotoxic agents (e.g., aminoglycosides): increased risk of kidney injury; assess renal markers regularly.

Frequently asked questions

What infections is Imicilast used to treat?+
Imicilast is indicated for severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, skin and soft‑tissue infections, hospital‑acquired pneumonia, and bacterial meningitis. It is used in hospitalized patients where broad‑spectrum coverage is required.
How does the combination of imipenem and cilastatin work?+
Imipenem disrupts bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, leading to cell death. Cilastatin inhibits the renal enzyme dehydropeptidase I, which would otherwise degrade imipenem, thereby extending its antibacterial activity and improving renal safety.
What is the usual dose of Imicilast?+
The dosing regimen for Imicilast is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and local antimicrobial guidelines. Specific dosage instructions should be obtained from the treating physician.
Is Imicilast safe to use during pregnancy or breastfeeding?+
Imicilast should be used during pregnancy or lactation only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians must evaluate the risk‑benefit profile and consider alternative therapies when appropriate.
How do I order Imicilast from GNH USA?+
To order Imicilast, submit an enquiry on the product page at gnh-usa.com specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.
How does Imicilast compare with other carbapenem antibiotics?+
Imicilast (imipenem/cilastatin) offers a broad spectrum of activity against Gram‑negative, Gram‑positive, and anaerobic bacteria, similar to other carbapenems like meropenem. Its unique cilastatin component protects imipenem from renal degradation, which can provide more stable plasma concentrations compared with agents lacking this protection.
What are the recommended storage conditions for Imicilast?+
Imicilast should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect from light, and avoid freezing or shaking the solution to maintain stability and potency.
How is Imicilast administered to patients?+
Imicilast is administered intravenously by a healthcare professional. The injection is reconstituted according to the manufacturer's instructions and infused over a specified period, typically 30 minutes, under aseptic conditions.
What are the most serious risks associated with Imicilast?+
Serious risks include the potential for seizures, especially in patients with renal impairment or pre‑existing CNS disorders, severe allergic reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Prompt recognition and management of these events are essential.
Who should not receive Imicilast?+
Patients with a known hypersensitivity to imipenem, cilastatin, or any β‑lactam antibiotics should not receive Imicilast. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those receiving interacting medications listed as major interactions.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Product details

Drug
Cilastatin, Imipenem Anhydrate
Route
Intravenous Use
Manufacturer
Sapiens Pharmaceuticals Ltd
Origin
EU

Related products